Already a DIA Member? Sign in. Not a member? Join.

Iniciar sesión

¿Ha olvidado su ID de usuario? or ¿Ha olvidado su contraseña?

Not a Member?

Create Account and Join

Bethesda North Marriott Hotel and Conference Center

20 sep 2018 7:00 a.m. - 21 sep 2018 12:45 p.m.

5701 Marinelli Road, , North Bethesda, MD 20852 , USA

Advancing the Science of Study Endpoints

Session 9: Selecting COA Endpoints and Analyzing COA Data in Rare Disease - Dealing with Small Sample Sizes and Heterogeneity

Session Chair(s)

Emuella  Flood

Emuella Flood

Director, Patient-Reported Outcomes

AstraZeneca, United States

Rare disease populations are typically small and heterogeneous, and often involve different subtypes, such as specific gene mutation subgroups, further reducing sample sizes. Specific COA-related challenges related to small sample sizes and heterogeneity of rare diseases include the selection and validation of COA measures and analyzing and interpreting the COA data to support treatment benefit. This session will identify the challenges of selecting COA endpoints and analyzing COA data in rare disease populations, including in evaluating psychometric properties of COA instruments. Potential Solutions will be offered, illustrated though case examples. The regulatory perspective on addressing these challenges will also be presented.

Learning Objective : At the conclusion of this session, participants should be able to:
  • Identify the challenges of COA endpoint selection and analysis in rare disease populations and potential solutions, such as the use of RWE and composite endpoints
  • Employ strategies to perform psychometric validation in small, heterogeneous samples
  • Discuss the regulatory perspective on endpoint selection and analysis in rare disease

Speaker(s)

Laura Lee  Johnson, PhD

Selecting COA Endpoints and Analyzing COA Data in Rare Disease-Dealing with Small Sample Sizes and Heterogeneity

Laura Lee Johnson, PhD

FDA, United States

Director, Division of Biometrics III, Office of Biostatistics, OTS, CDER

Linda  Nelsen, MHS

Selection and Development of Patient-focused COAs for Rare Disease Clinical Trials

Linda Nelsen, MHS

GlaxoSmithKline, United States

Senior Director and Head, Oncology Patient-Centered Outcomes

Jeffrey  Palmer

Selecting COA Endpoints and Analyzing COA Data in Rare Disease-Dealing with Small Sample Sizes and Heterogeneity

Jeffrey Palmer

Pfizer Inc, United States

Senior Director, Biostatistics

R.J.  Wirth, PhD

Psychometric Evaluation with Small Samples

R.J. Wirth, PhD

Vector Psychometric Group, LLC, United States

CEO

¿Tiene una cuenta?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.